Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 7, 2014, Pages 1186-1195

  Oze, Tsugiko ^a   Hiramatsu, Naoki ^a   Yakushijin, Takayuki ^a   Miyazaki, Masanori ^a   Yamada, Akira ^b   Oshita, Masahide ^c   Hagiwara, Hideki ^d   Mita, Eiji ^e   Ito, Toshifumi ^f   Fukui, Hiroyuki ^g   Inui, Yoshiaki ^h   Hijioka, Taizo ⁱ   Inada, Masami ^j   Katayama, Kazuhiro ^k   Tamura, Shinji ^l   Yoshihara, Harumasa ^m   Inoue, Atsuo ⁿ   Imai, Yasuharu ^o   Hayashi, Eijiro ^p   Kato, Michio ^q   Miyagi, Takuya ^a   Yoshida, Yuichi ^a   Tatsumi, Tomohide ^a   Kasahara, Akinori ^a   Hamasaki, Toshimitsu ^a   Hayashi, Norio ^d   Takehara, Tetsuo ^a   more..

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SUMITOMO HOSPITAL   (Japan)

^c OSAKA POLICE HOSPITAL   (Japan)

^d KANSAI ROSAI HOSPITAL   (Japan)

^e OSAKA NATIONAL HOSPITAL   (Japan)

^f OSAKA KOSEI NENKIN HOSPITAL   (Japan)

^g Yao Municipal Hospital   (Japan)

^h Hyogo Prefectural Nishinomiya Hospital   (Japan)

ⁱ MINAMI OSAKA GENERAL HOSPITAL   (Japan)

^j TOYONAKA MUNICIPAL HOSPITAL   (Japan)

^k OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^l Minoh City Hospital   (Japan)

^m OSAKA ROSAI HOSPITAL   (Japan)

ⁿ OSAKA GENERAL MEDICAL CENTER   (Japan)

^o IKEDA MUNICIPAL HOSPITAL   (Japan)

^p Kinki Central Hospital of Mutual Association of Public School Teachers   (Japan)

^q National Hospital Organizaton Minami Wakayama Medical Center   (Japan)

more..

Author keywords

ALT; Liver cancer; Outcome; Response to therapy; Risk factor

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA FETOPROTEIN; BILIRUBIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; URSODEOXYCHOLIC ACID; VIRUS RNA;

ADULT; AGE DISTRIBUTION; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANTIVIRAL ACTIVITY; ARTICLE; BILIRUBIN BLOOD LEVEL; BIOCHEMISTRY; CANCER INCIDENCE; CANCER RISK; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ECHOGRAPHY; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HUMAN; JAPAN; LIVER ANGIOGRAPHY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PREMEDICATION; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RELAPSE; RISK FACTOR; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84902550644     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.11.033     Document Type: Article

References (15)

1. Kasahara A., Hayashi N., Mochizuki K., et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology 1998, 27:1394-1402.
2. Yoshida H., Shiratori Y., Moriyama M., et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999, 131:174-181.
3. Toyoda H., Kumada T., Tokuda A., et al. Long-term follow-up of sustained responders to interferon therapy, in patients with chronic hepatitis C. JViral Hepat 2000, 7:414-419.
4. Tokita H., Fukui H., Tanaka A., et al. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy. JGastroenterol Hepatol 2005, 20:752-758.
5. George S.L., Bacon B.R., Brunt E.M., et al. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology 2009, 49:729-738.
6. Hagiwara H., Hayashi N., Kasahara A., et al. Long-term biochemical and virological response to natural interferon-alpha in patients with chronic hepatitis C. Dig Dis Sci 1996, 41:1001-1007.
7. Arase Y., Ikeda K., Suzuki F., et al. Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C. JMed Virol 2007, 79:1095-1102.
8. Hiramatsu N., Hayashi N., Kasahara A., et al. Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha. JHepatol 1995, 22:135-142.
9. Bedossa P., Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996, 24:289-293.
10. Kumada T., Toyoda H., Kiriyama S., et al. Predictive value of tumor markers for hepatocarcinogenesis in patients with hepatitis C virus. JGastroenterol 2011, 46:536-544.
11. Tarao K., Rino Y., Ohkawa S., et al. Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis. Cancer 1999, 86:589-595.
12. Cardoso A.C., Moucari R., Figueiredo-Mendes C., et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. JHepatol 2010, 52:652-657.
13. Ogawa E., Furusyo N., Kajiwara E., et al. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study. JHepatol 2013, 58:495-501.
14. Lok A.S., Everhart J.E., Wright E.C., et al. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology 2011, 140:840-849.
15. Richardson P., Duan Z., Kramer J., et al. Determinants of serum alpha-fetoprotein levels in hepatitis C-infected patients. Clin Gastroenterol Hepatol 2012, 10:428-433.